- Home
- ATAI vs ITOS Comparison
ATAI vs ITOS Comparison
Compare ATAI & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ITOS
- Stock Information
- Founded
- ATAI 2018
- ITOS 2011
- Country
- ATAI Germany
- ITOS United States
- Employees
- ATAI N/A
- ITOS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ATAI Health Care
- ITOS Health Care
- Exchange
- ATAI Nasdaq
- ITOS Nasdaq
- Market Cap
- ATAI 444.7M
- ITOS 381.2M
- IPO Year
- ATAI 2021
- ITOS 2020
- Fundamental
- Price
- ATAI $2.75
- ITOS $10.07
- Analyst Decision
- ATAI Strong Buy
- ITOS Hold
- Analyst Count
- ATAI 2
- ITOS 6
- Target Price
- ATAI $11.00
- ITOS $10.60
- AVG Volume (30 Days)
- ATAI 5.7M
- ITOS 871.5K
- Earning Date
- ATAI 08-12-2025
- ITOS 08-07-2025
- Dividend Yield
- ATAI N/A
- ITOS N/A
- EPS Growth
- ATAI N/A
- ITOS N/A
- EPS
- ATAI N/A
- ITOS N/A
- Revenue
- ATAI $1,863,000.00
- ITOS $35,000,000.00
- Revenue This Year
- ATAI $554.22
- ITOS N/A
- Revenue Next Year
- ATAI N/A
- ITOS N/A
- P/E Ratio
- ATAI N/A
- ITOS N/A
- Revenue Growth
- ATAI 572.56
- ITOS 177.89
- 52 Week Low
- ATAI $1.03
- ITOS $4.80
- 52 Week High
- ATAI $2.99
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- ATAI 66.80
- ITOS 62.61
- Support Level
- ATAI $2.62
- ITOS $9.95
- Resistance Level
- ATAI $2.96
- ITOS $10.21
- Average True Range (ATR)
- ATAI 0.23
- ITOS 0.15
- MACD
- ATAI 0.04
- ITOS -0.09
- Stochastic Oscillator
- ATAI 76.53
- ITOS 53.33
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.